Bausch & Lomb Corp — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Q2 2026 revenue reached $1.394B (+9% reported, +8% constant currency) vs. $1.278B in Q2 2025. All three segments grew: Vision Care $784M (+4%), Surgical $256M (+19%, driven by premium IOLs at 175% growth), Pharmaceuticals $354M (+15%, MIEBO/XIIDRA +27%). GAAP net loss improved to -$14M from -$62M; Adjusted EBITDA excluding Acquired IPR&D rose to $246M from $192M (+28%). Company raised FY 2026 guidance: revenue $5.44–5.54B (vs. prior $5.42–5.52B), Adjusted EBITDA excluding IPR&D $1.025–1.075B (vs. prior $1.01–1.06B).
Why this rating
Strong organic growth (+8% constant currency), margin expansion, and guidance raise materially improve a ~$557M market-cap company. Surgical +16% and Pharma +14% are substantial; operating income swung to +$83M. Not transformational but meaningful operational momentum.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.